Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 141 articles: HTML format

Single Articles

March 2023
1. GURSKA LM, Okabe R, Schurer A, Tong MM, et al
   Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
   Clin Cancer Res. 2023;29:943-956.
   PubMed     Abstract available
   
   
   February 2023
2. ROSNER S, Reuss JE, Zahurak M, Zhang J, et al
   Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2023;29:705-710.
   PubMed     Abstract available
   
   
   
3. WIJETUNGA NA, Goglia AG, Weinhold N, Berger MF, et al
   Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
   Clin Cancer Res. 2023;29:775-783.
   PubMed     Abstract available
   
   
   
4. OWEN DH, Benner B, Wei L, Sukrithan V, et al
   A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
   Clin Cancer Res. 2023;29:731-741.
   PubMed     Abstract available
   
   
   
5. ROSNER S, Reuss JE, Zahurak M, Zhang J, et al
   Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2023 Feb 15:OF1-OF6. doi: 10.1158/1078-0432.CCR-22-2994.
   PubMed     Abstract available
   
   
   
6. LEE HS, Jang HJ, Ramineni M, Wang DY, et al
   A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
   Clin Cancer Res. 2023;29:548-559.
   PubMed     Abstract available
   
   
   
7. AUGUSTIN RC, Bao R, Luke JJ
   Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones.
   Clin Cancer Res. 2023;29:505-507.
   PubMed     Abstract available
   
   
   
8. WANG J, Guo W, Wang X, Tang X, et al
   Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
   Clin Cancer Res. 2023;29:659-666.
   PubMed     Abstract available
   
   
   January 2023
9. ZHANG Y, Tacheva-Grigorova SK, Sutton J, Melton Z, et al
   Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
   Clin Cancer Res. 2023 Jan 23:OF1-OF15. doi: 10.1158/1078-0432.CCR-22-2293.
   PubMed     Abstract available
   
   
   
10. JONES R, Plummer R, Moreno V, Carter L, et al
    A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
    Clin Cancer Res. 2023;29:331-340.
    PubMed     Abstract available
    
    
    
11. OH SY, Lee YW, Lee EJ, Kim JH, et al
    Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
    Clin Cancer Res. 2023;29:221-232.
    PubMed     Abstract available
    
    
    
12. WAINBERG ZA, Singh AS, Konecny GE, McCann KE, et al
    Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clin Cancer Res. 2023;29:40-49.
    PubMed     Abstract available
    
    
    December 2022
13. PALANKI R, Swingle KL, Mitchell MJ
    A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma.
    Clin Cancer Res. 2022;28:5010-5012.
    PubMed     Abstract available
    
    
    
14. NASH AM, Aghlara-Fotovat S, Castillio B, Hernandez A, et al
    Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors.
    Clin Cancer Res. 2022;28:5121-5135.
    PubMed     Abstract available
    
    
    November 2022
15. ANAGNOSTOU V, Luke JJ
    Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade.
    Clin Cancer Res. 2022;28:4835-4837.
    PubMed     Abstract available
    
    
    
16. LIM EA, Bendell JC, Falchook GS, Bauer TM, et al
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Clin Cancer Res. 2022;28:4871-4884.
    PubMed     Abstract available
    
    
    
17. HUMMELINK K, van der Noort V, Muller M, Schouten RD, et al
    PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
    Clin Cancer Res. 2022;28:4893-4906.
    PubMed     Abstract available
    
    
    
18. POULIKAKOS PI, Sullivan RJ, Yaeger R
    Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.
    Clin Cancer Res. 2022;28:4618-4628.
    PubMed     Abstract available
    
    
    October 2022
19. BRAMAN N, Prasanna P, Bera K, Alilou M, et al
    Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.
    Clin Cancer Res. 2022;28:4410-4424.
    PubMed     Abstract available
    
    
    
20. SUGIMOTO A, Matsumoto S, Udagawa H, Itotani R, et al
    A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid).
    Clin Cancer Res. 2022 Oct 6. pii: 709652. doi: 10.1158/1078-0432.CCR-22-1749.
    PubMed     Abstract available
    
    
    
21. JUNG HA, Lim J, Choi YL, Lee SH, et al
    Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
    Clin Cancer Res. 2022;28:4312-4321.
    PubMed     Abstract available
    
    
    September 2022
22. ROCHIGNEUX P, Lisberg A, Garcia A, Granjeaud S, et al
    Mass cytometry reveals classical monocytes, NK cells and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in lung cancer patients.
    Clin Cancer Res. 2022 Sep 27. pii: 709487. doi: 10.1158/1078-0432.CCR-22-1386.
    PubMed     Abstract available
    
    
    
23. ROTOLO R, Leuci V, Donini C, Galvagno F, et al
    Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells.
    Clin Cancer Res. 2022 Sep 27. pii: 709485. doi: 10.1158/1078-0432.CCR-22-0761.
    PubMed     Abstract available
    
    
    
24. DUKE ES, Stapleford L, Drezner N, Amatya AK, et al
    FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Clin Cancer Res. 2022 Sep 16. pii: 709236. doi: 10.1158/1078-0432.CCR-22-2072.
    PubMed     Abstract available
    
    
    
25. GUIDRY K, Vasudevaraja V, Labbe K, Mohamed H, et al
    DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome.
    Clin Cancer Res. 2022;28:3824-3835.
    PubMed     Abstract available
    
    
    
26. KENNEDY GT, Holt DE, Azari FS, Bernstein E, et al
    A Cathepsin-Targeted Quenched Activity-Based Probe Facilitates Enhanced Detection of Human Tumors during Resection.
    Clin Cancer Res. 2022;28:3729-3741.
    PubMed     Abstract available
    
    
    
27. MACK PC, Miao J, Redman MW, Moon J, et al
    Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
    Clin Cancer Res. 2022;28:3752-3760.
    PubMed     Abstract available
    
    
    
28. YAP TA, Gainor JF, Callahan MK, Falchook GS, et al
    First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
    Clin Cancer Res. 2022;28:3695-3708.
    PubMed     Abstract available
    
    
    August 2022
29. MAHADEVAN NR, Sholl LM
    To Rb or Not to Rb: Uncovering Unique Subsets of Small Cell Lung Carcinoma.
    Clin Cancer Res. 2022 Aug 31. pii: 708945. doi: 10.1158/1078-0432.CCR-22-2187.
    PubMed     Abstract available
    
    
    
30. TANIGUCHI Y, Shimokawa T, Takiguchi Y, Misumi T, et al
    A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small-cell lung cancer: TORG1630.
    Clin Cancer Res. 2022 Aug 18. pii: 708059. doi: 10.1158/1078-0432.CCR-22-1687.
    PubMed     Abstract available
    
    
    
31. OZCAN G, Singh M, Vredenburgh JJ
    Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.
    Clin Cancer Res. 2022 Aug 16. pii: 707826. doi: 10.1158/1078-0432.CCR-22-1585.
    PubMed     Abstract available
    
    
    
32. KIM TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al
    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:3452-3463.
    PubMed     Abstract available
    
    
    
33. HIATT JB, Sandborg H, Garrison SM, Arnold HU, et al
    Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing.
    Clin Cancer Res. 2022 Aug 3. pii: 707373. doi: 10.1158/1078-0432.CCR-22-1128.
    PubMed     Abstract available
    
    
    
34. WEI S, Gao X, Tang M, Li J, et al
    Perioperative ctDNA-Based MRD Detection in NSCLC- Letter.
    Clin Cancer Res. 2022;28:3400.
    PubMed    
    
    
    
35. XIA L, Chen W, Liu L
    Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
    Clin Cancer Res. 2022;28:3401.
    PubMed    
    
    
    July 2022
36. HUNIHAN L, Zhao D, Lazowski H, Li M, et al
    RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
    Clin Cancer Res. 2022;28:3091-3103.
    PubMed     Abstract available
    
    
    
37. BARLESI F, Tomasini P, Karimi M, Michiels S, et al
    Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
    Clin Cancer Res. 2022 Jul 8. pii: 706925. doi: 10.1158/1078-0432.CCR-22-0371.
    PubMed     Abstract available
    
    
    
38. FEBRES ALDANA CA, Chang JC, Ptashkin R, Wang Y, et al
    Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset.
    Clin Cancer Res. 2022 Jul 6. pii: 706889. doi: 10.1158/1078-0432.CCR-22-1115.
    PubMed     Abstract available
    
    
    June 2022
39. SCHOENFELD AJ, Rizvi HA, Memon D, Shaverdian N, et al
    Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer.
    Clin Cancer Res. 2022 Jun 29. pii: 705289. doi: 10.1158/1078-0432.CCR-22-0657.
    PubMed     Abstract available
    
    
    
40. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
    Clin Cancer Res. 2022 Jun 28:OF1-OF7. doi: 10.1158/1078-0432.CCR-22-0602.
    PubMed     Abstract available
    
    
    
41. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).
    Clin Cancer Res. 2022 Jun 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-21-4329.
    PubMed     Abstract available
    
    
    
42. GUAN S, Chen X, Chen Y, Xie W, et al
    FOXM1 variant contributes to gefitinib resistance via activating wnt/beta-catenin signal pathway in non-small cell lung cancer patients.
    Clin Cancer Res. 2022 Jun 13. pii: 704872. doi: 10.1158/1078-0432.CCR-22-0791.
    PubMed     Abstract available
    
    
    
43. MURCIANO-GOROFF YR, Harada G, Drilon A
    An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
    Clin Cancer Res. 2022;28:2477-2479.
    PubMed     Abstract available
    
    
    
44. TAKEMOTO A, Takagi S, Ukaji T, Gyobu N, et al
    Targeting Podoplanin for the Treatment of Osteosarcoma.
    Clin Cancer Res. 2022;28:2633-2645.
    PubMed     Abstract available
    
    
    
45. ROCHA P, Zhang J, Laza-Briviesca R, Cruz-Bermudez A, et al
    Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
    Clin Cancer Res. 2022;28:2461-2473.
    PubMed     Abstract available
    
    
    
46. TSENG D, Gainor JF
    Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.
    Clin Cancer Res. 2022;28:2206-2208.
    PubMed     Abstract available
    
    
    
47. PATIL T, Bunn PA
    Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
    Clin Cancer Res. 2022;28:2204-2205.
    PubMed     Abstract available
    
    
    
48. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:2257-2269.
    PubMed     Abstract available
    
    
    
49. AKINBORO O, Larkins E, Pai-Scherf LH, Mathieu LN, et al
    FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
    Clin Cancer Res. 2022;28:2221-2228.
    PubMed     Abstract available
    
    
    
50. JUNG HA, Park S, Choi YL, Lee SH, et al
    Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
    Clin Cancer Res. 2022;28:2321-2328.
    PubMed     Abstract available
    
    
    May 2022
51. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).
    Clin Cancer Res. 2022 May 26. pii: 699251. doi: 10.1158/1078-0432.CCR-22-0602.
    PubMed     Abstract available
    
    
    
52. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).
    Clin Cancer Res. 2022 May 26. pii: 699247. doi: 10.1158/1078-0432.CCR-21-4329.
    PubMed     Abstract available
    
    
    
53. KOMMALAPATI A, Mansfield AS
    Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases.
    Clin Cancer Res. 2022 May 24. pii: 699172. doi: 10.1158/1078-0432.CCR-22-1137.
    PubMed     Abstract available
    
    
    
54. FRIZZIERO M, Kilgour E, Simpson KL, Rothwell DG, et al
    Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
    Clin Cancer Res. 2022;28:1999-2019.
    PubMed     Abstract available
    
    
    
55. MOORTHI S, Berger AH
    All about that Ras: Novel fusion drives Ras pathway activation in lung cancer.
    Clin Cancer Res. 2022 May 5. pii: 696314. doi: 10.1158/1078-0432.CCR-22-0736.
    PubMed     Abstract available
    
    
    
56. TON TGN, Pal N, Trinh H, Mahrus S, et al
    Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data.
    Clin Cancer Res. 2022 May 5. pii: 696304. doi: 10.1158/1078-0432.CCR-22-0471.
    PubMed     Abstract available
    
    
    April 2022
57. SONG L, Xiong H, Li J, Liao W, et al
    Correction: Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NFkappaB Pathway in Human Non-small Cell Lung Cancer.
    Clin Cancer Res. 2022;28:1740.
    PubMed    
    
    
    
58. NAKAJIMA EC, Drezner N, Li X, Mishra-Kalyani PS, et al
    FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Clin Cancer Res. 2022;28:1482-1486.
    PubMed     Abstract available
    
    
    
59. SABARI JK, Velcheti V, Shimizu K, Strickland MR, et al
    Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2022 Apr 11. pii: 694212. doi: 10.1158/1078-0432.CCR-22-0383.
    PubMed     Abstract available
    
    
    
60. DEMETRI GD, De Braud F, Drilon A, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2022;28:1302-1312.
    PubMed     Abstract available
    
    
    March 2022
61. ROSNER S, Spira AI
    Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.
    Clin Cancer Res. 2022;28:1055-1057.
    PubMed     Abstract available
    
    
    
62. LE X, Sakai H, Felip E, Veillon R, et al
    Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
    Clin Cancer Res. 2022;28:1117-1126.
    PubMed     Abstract available
    
    
    
63. DZIADZIUSZKO R, Peters S, Mok T, Camidge DR, et al
    Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
    Clin Cancer Res. 2022 Mar 11. pii: 681795. doi: 10.1158/1078-0432.CCR-21-2840.
    PubMed     Abstract available
    
    
    
64. CHIAPPORI AA, Creelan B, Tanvetyanon T, Gray JE, et al
    Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 682078. doi: 10.1158/1078-0432.CCR-21-2742.
    PubMed     Abstract available
    
    
    
65. HAYASHI H, Sugawara S, Fukuda Y, Fujimoto D, et al
    A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
    Clin Cancer Res. 2022;28:893-902.
    PubMed     Abstract available
    
    
    February 2022
66. LEE JK, Hazar-Rethinam M, Decker B, Gjoerup O, et al
    The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
    Clin Cancer Res. 2022;28:728-737.
    PubMed     Abstract available
    
    
    
67. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-0344.
    PubMed     Abstract available
    
    
    
68. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 11. pii: 681703. doi: 10.1158/1078-0432.CCR-21-0344.
    PubMed     Abstract available
    
    
    
69. NAKAJIMA EC, Vellanki PJ, Larkins E, Chatterjee S, et al
    FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2022;28:446-451.
    PubMed     Abstract available
    
    
    January 2022
70. CHOW LQM, Barlesi F, Bertino EM, van den Bent MJ, et al
    ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-1838.
    PubMed     Abstract available
    
    
    
71. RICCIUTI B, Son J, Okoro JJ, Mira A, et al
    Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2719.
    PubMed     Abstract available
    
    
    
72. TULLY KM, Tendler S, Carter LM, Sharma SK, et al
    Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-1533.
    PubMed     Abstract available
    
    
    
73. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
    Clin Cancer Res. 2022;28:428.
    PubMed    
    
    
    
74. MATHIEU LN, Larkins E, Akinboro O, Roy P, et al
    FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Clin Cancer Res. 2022;28:249-254.
    PubMed     Abstract available
    
    
    
75. MAJEM M, Goldman JW, John T, Grohe C, et al
    Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial.
    Clin Cancer Res. 2022 Jan 10. pii: 1078-0432.CCR-21-3530.
    PubMed     Abstract available
    
    
    
76. GAO Y, Paivinen P, Tripathi S, Domenech-Moreno E, et al
    Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
    Clin Cancer Res. 2022;28:227-237.
    PubMed     Abstract available
    
    
    
77. LEE JC, Green MD, Huppert LA, Chow C, et al
    The Liver-Immunity Nexus and Cancer Immunotherapy.
    Clin Cancer Res. 2022;28:5-12.
    PubMed     Abstract available
    
    
    December 2021
78. YONESAKA K, Tanizaki J, Maenishi O, Haratani K, et al
    HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3359.
    PubMed     Abstract available
    
    
    
79. JIN Y, Chen Y, Tang H, Hubert SM, et al
    Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-1943.
    PubMed     Abstract available
    
    
    
80. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    PubMed     Abstract available
    
    
    
81. HANNAN R, Mohamad O, Diaz de Leon A, Manna S, et al
    Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.
    Clin Cancer Res. 2021;27:6716-6725.
    PubMed     Abstract available
    
    
    
82. LEE CJ, Schoffski P, Modave E, van Wezel T, et al
    Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib.
    Clin Cancer Res. 2021;27:6737-6748.
    PubMed     Abstract available
    
    
    November 2021
83. XIA L, Mei J, Kang R, Deng S, et al
    Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3044.
    PubMed     Abstract available
    
    
    
84. SONG Z, Lv D, Chen SQ, Huang J, et al
    Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Clin Cancer Res. 2021 Nov 9. pii: 1078-0432.CCR-21-2936.
    PubMed     Abstract available
    
    
    
85. ZHOU Q, Wu L, Hu P, An T, et al
    A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2595.
    PubMed     Abstract available
    
    
    
86. BISWAS T, Dowlati A, Kunos CA, Pink JJ, et al
    Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2025.
    PubMed     Abstract available
    
    
    
87. CASARRUBIOS M, Cruz-Bermudez A, Nadal E, Insa A, et al
    Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
    Clin Cancer Res. 2021;27:5878-5890.
    PubMed     Abstract available
    
    
    
88. CHUA KP, Teng YHF, Tan AC, Takano A, et al
    Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.
    Clin Cancer Res. 2021;27:5939-5950.
    PubMed     Abstract available
    
    
    October 2021
89. MEHTA S, Fiorelli R, Bao X, Pennington-Krygier C, et al
    A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
    Clin Cancer Res. 2021 Oct 26. pii: 1078-0432.CCR-21-1096.
    PubMed     Abstract available
    
    
    
90. GAVRIELATOU N, Liu Y, Vathiotis I, Zugazagoitia J, et al
    Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Oct 22. pii: 1078-0432.CCR-21-2649.
    PubMed     Abstract available
    
    
    September 2021
91. KAWAZOE A, Itahashi K, Yamamoto N, Kotani D, et al
    TAS-116 plus nivolumab in patients with colorectal cancer and other solid tumors: an, open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1929.
    PubMed     Abstract available
    
    
    
92. PORCIUNCULA A, Morgado M, Gupta R, Syrigos K, et al
    Spatial mapping and immunomodulatory role of the OX40/OX40L pathway in human non-small cell lung cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-0987.
    PubMed     Abstract available
    
    
    August 2021
93. SHI J, Wang Z, Zhang J, Xu Y, et al
    Genomic landscape and tumor mutational burden determination of circulating tumor DNA in over 5,000 Chinese lung cancer patients.
    Clin Cancer Res. 2021 Aug 26. pii: 1078-0432.CCR-21-1537.
    PubMed     Abstract available
    
    
    
94. CAMIDGE DR, Morgensztern D, Heist RS, Barve M, et al
    Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res. 2021 Aug 23. pii: 1078-0432.CCR-21-0765.
    PubMed     Abstract available
    
    
    
95. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available
    
    
    
96. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    KRAS inhibitor-resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
    Clin Cancer Res. 2021 Aug 7. pii: 1078-0432.CCR-21-0856.
    PubMed     Abstract available
    
    
    
97. SUBBIAH V, Gainor JF, Oxnard GR, Tan DSW, et al
    Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
    Clin Cancer Res. 2021;27:4160-4167.
    PubMed     Abstract available
    
    
    
98. KIM SY, Kim SM, Lim S, Lee JY, et al
    Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:4397-4409.
    PubMed     Abstract available
    
    
    
99. CONFORTI F, Pala L, Pagan E, Bagnardi V, et al
    Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.
    Clin Cancer Res. 2021;27:4311-4324.
    PubMed     Abstract available
    
    
    July 2021
100. NAKAGAWA K, Nadal E, Garon EB, Nishio M, et al
     RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer.
     Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0273.
     PubMed     Abstract available
     
     
     
101. KOCH AL, Vellanki PJ, Drezner N, Li X, et al
     FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.
     Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-1034.
     PubMed     Abstract available
     
     
     
102. CHANG JC, Offin M, Falcon C, Brown D, et al
     Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
     Clin Cancer Res. 2021;27:4066-4076.
     PubMed     Abstract available
     
     
     
103. LUO J, Martucci VL, Quandt Z, Groha S, et al
     Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
     Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
     PubMed     Abstract available
     
     
     
104. FOSTER JH, Voss SD, Hall DC, Minard CG, et al
     Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).
     Clin Cancer Res. 2021;27:3543-3548.
     PubMed     Abstract available
     
     
     June 2021
105. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
     A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
     Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
     PubMed     Abstract available
     
     
     
106. RAGHAV K, Hwang H, Jacome AA, Bhang E, et al
     Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.
     Clin Cancer Res. 2021;27:3414-3421.
     PubMed     Abstract available
     
     
     
107. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
     A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
     Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
     PubMed     Abstract available
     
     
     
108. LEWIS CD, Singh AK, Hsu FF, Thotala D, et al
     Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.
     Clin Cancer Res. 2021;27:3224-3233.
     PubMed     Abstract available
     
     
     
109. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
     An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
     Clin Cancer Res. 2021;27:3167-3177.
     PubMed     Abstract available
     
     
     May 2021
110. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
     FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
     Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
     PubMed     Abstract available
     
     
     
111. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
     First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
     Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
     PubMed     Abstract available
     
     
     
112. CHOUDHURY NJ, Schoenfeld AJ, Flynn J, Falcon CJ, et al
     Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
     Clin Cancer Res. 2021;27:2920-2927.
     PubMed     Abstract available
     
     
     
113. BYERS LA, Bentsion D, Gans S, Penkov K, et al
     Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
     Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4259.
     PubMed     Abstract available
     
     
     
114. JONES GD, Caso R, Tan KS, Mastrogiacomo B, et al
     KRAS (G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
     Clin Cancer Res. 2021;27:2604-2612.
     PubMed     Abstract available
     
     
     April 2021
115. CHEN K, Nie Y, Park S, Zhang K, et al
     Development and Validation of Machine Learning-based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts.
     Clin Cancer Res. 2021;27:2255-2265.
     PubMed     Abstract available
     
     
     
116. OEHL K, Vrugt B, Wagner U, Kirschner MB, et al
     Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma.
     Clin Cancer Res. 2021;27:2277-2291.
     PubMed     Abstract available
     
     
     
117. DREYFUSS AD, Goia D, Shoniyozov K, Shewale SV, et al
     A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance.
     Clin Cancer Res. 2021;27:2266-2276.
     PubMed     Abstract available
     
     
     
118. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
     A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
     PubMed     Abstract available
     
     
     March 2021
119. BERTINO EM, Gentzler RD, Clifford S, Kolesar J, et al
     Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
     Clin Cancer Res. 2021;27:1604-1611.
     PubMed     Abstract available
     
     
     
120. SI H, Kuziora M, Quinn KJ, Helman E, et al
     A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
     Clin Cancer Res. 2021;27:1631-1640.
     PubMed     Abstract available
     
     
     
121. SITTHIDEATPHAIBOON P, Galan-Cobo A, Negrao MV, Qu X, et al
     STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
     Clin Cancer Res. 2021;27:1720-1733.
     PubMed     Abstract available
     
     
     
122. AGGARWAL C, Thompson JC, Carpenter EL
     Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
     Clin Cancer Res. 2021;27:1581.
     PubMed    
     
     
     
123. XUE Z, Guo X, Wen J, Cai W, et al
     Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
     Clin Cancer Res. 2021;27:1580.
     PubMed    
     
     
     
124. ESTRADA-BERNAL A, Le AT, Doak AE, Tirunagaru VG, et al
     Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
     Clin Cancer Res. 2021;27:1463-1475.
     PubMed     Abstract available
     
     
     
125. HACKENG WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, et al
     Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.
     Clin Cancer Res. 2021;27:1341-1350.
     PubMed     Abstract available
     
     
     
126. ZHOU C, Wang Y, Zhao J, Chen G, et al
     Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
     Clin Cancer Res. 2021;27:1296-1304.
     PubMed     Abstract available
     
     
     
127. TANIMOTO A, Matsumoto S, Takeuchi S, Arai S, et al
     Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
     Clin Cancer Res. 2021;27:1410-1420.
     PubMed     Abstract available
     
     
     February 2021
128. GARON EB
     Osimertinib plus Ramucirumab: The Best of Both Worlds?
     Clin Cancer Res. 2021;27:905-907.
     PubMed     Abstract available
     
     
     
129. SKOULIDIS F
     Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.
     Clin Cancer Res. 2021;27:913-915.
     PubMed     Abstract available
     
     
     
130. HELLMANN MD, Janne PA, Opyrchal M, Hafez N, et al
     Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
     Clin Cancer Res. 2021;27:1019-1028.
     PubMed     Abstract available
     
     
     
131. TAN Y, Sementino E, Cheung M, Peri S, et al
     Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
     Clin Cancer Res. 2021;27:1200-1213.
     PubMed     Abstract available
     
     
     
132. DAEMEN A, Cooper JE, Myrta S, Wongchenko MJ, et al
     Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
     Clin Cancer Res. 2021;27:1162-1173.
     PubMed     Abstract available
     
     
     
133. AI X, Cui J, Zhang J, Chen R, et al
     Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
     Clin Cancer Res. 2021;27:704-712.
     PubMed     Abstract available
     
     
     
134. GUO R, Offin M, Brannon AR, Chang J, et al
     MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
     Clin Cancer Res. 2021;27:799-806.
     PubMed     Abstract available
     
     
     January 2021
135. RAHMA OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al
     Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
     Clin Cancer Res. 2021;27:485-491.
     PubMed     Abstract available
     
     
     
136. GEIGER T, Beck L, Harel M, Yu S, et al
     Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ-Specificity and Treatment Resistance.
     Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-3752.
     PubMed     Abstract available
     
     
     
137. DEUTSCH E, Chargari C, Weichselbaum RR, Levy A, et al
     Drug-Radiotherapy Combination Trial Developments-Response.
     Clin Cancer Res. 2021;27:356.
     PubMed    
     
     
     
138. EVANS JR, Cuneo KC, Lawrence TS
     Drug-Radiotherapy Combination Trial Developments-Letter.
     Clin Cancer Res. 2021;27:355.
     PubMed    
     
     
     
139. COLCLOUGH N, Chen K, Johnstrom P, Strittmatter N, et al
     Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
     Clin Cancer Res. 2021;27:189-201.
     PubMed     Abstract available
     
     
     November 2020
140. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
     FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
     Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
     PubMed     Abstract available
     
     
     April 2020
141. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
     PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
     Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: